Crucial drugs to be more affordable after GST cut

The government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart conditions, aiming to make healthcare more affordable. Key drugs like Risdiplam and daratumumab will now have zero GST, benefiting patients with spinal muscular atrophy and multiple myeloma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3D0ben
via IFTTT

Read More

Centre set to amend rules to simplify drug testing process

The Indian government is amending drug regulations to expedite the approval process for clinical trials and bioavailability/bioequivalence studies. These changes aim to reduce the statutory processing time for test license applications from 90 to 45 days. By simplifying procedures and reducing the number of license applications, the government anticipates faster drug development and approval, benefiting stakeholders and optimizing resource allocation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kijh5TH
via IFTTT

Read More

Alkem's Enzene powers into US with $70 m investment

Enzene Biosciences, an Alkem Labs subsidiary, has inaugurated a new US manufacturing plant. The facility is located in New Jersey. This venture represents a $70 million investment. It aligns with calls to boost local pharma manufacturing. Enzene's technology offers cost-effective drug production. The company currently employs 50 people. Enzene plans to increase its workforce to 200.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FW6hpHG
via IFTTT

Read More

Singapore-based firm proposes to acquire 25% in Welcure Drugs & Pharma

Welcure Drugs & Pharmaceuticals receives an offer from Telexcell Trade. Telexcell Trade, based in Singapore, plans to acquire a 25 per cent stake. The indicative price is Rs 20 per share. This investment aims to expand Welcure's global presence. The all-cash investment is estimated at Rs 52 crore. Welcure intends to invest in an agro-pharma research lab.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oVTei6H
via IFTTT

Read More

Lupin gets USFDA nod for generic risperidone extended-release injectable suspension

Lupin Ltd. secured USFDA approval for its generic risperidone extended-release injectable suspension, a treatment for schizophrenia and bipolar disorder. This marks Lupin's first product utilizing Nanomi BV's technology, benefiting from 180-day competitive generic therapies exclusivity. The drug, with estimated annual sales of USD 190 million, expands access to complex injectables for patients globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5cr3uk
via IFTTT

Read More

Caplin Point arm gets USFDA nod for milrinone lactate in 5 pc dextrose injection

Caplin Point Laboratories' arm, Caplin Steriles, secured USFDA approval for its generic milrinone lactate in 5% dextrose injection. Indicated for acute decompensated heart failure, the injection is a generic version of Sanofi Aventis' PRIMACOR. The US market for this injection reached approximately USD 11 million in sales for the year ending July 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sRMWo3w
via IFTTT

Read More

Medical device manufacturers allowed to give free samples

Medical device companies in New Delhi can now give doctors free samples. There are rules for this. The sample's price must match what stockists pay. If the company bought the sample, that price counts. Company CEOs must ensure code compliance. Marketing costs must be disclosed yearly. This promotes ethical marketing and benefits both manufacturers and patients in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6CKwkI5
via IFTTT

Read More